标题: Long-term Lamivudine: experience in hepatitis B patients in a tertiary centre in [打印本页] 作者: StephenW 时间: 2011-8-4 09:11 标题: Long-term Lamivudine: experience in hepatitis B patients in a tertiary centre in
Long-term Lamivudine: experience in hepatitis B
patients in a tertiary centre in Western Australia
N MUWANWELLA,1 N KONTORINIS,1 L TARQUINIO,1
J FLEXMAN,2 W CHENG1
1Department of Gastroenterology and Hepatology,
2Infectious Diseases, Royal Perth Hospital, WA
Long-term treatment with Lamivudine is associated with high rates of
resistance, but some patients showed long term good viral suppression.
The objective of the study is to describe the clinical, biochemical and
virological outcomes of the patients who are treated with Lamivudine for
chornic hepatitis B (CHB) in Royal Perth Hospital, WA over the period of
15 years from 1995 to 2010.
Methods
Retrospective descriptive study of all patients with CHB seen
at the Liver Service. The primary end-point was HBeAg seroconversion,
and loss of HBV DNA. The secondary end-points included the proportion
of the patients who are still on Lamivudine, serologic recurrence and reappearance
of HBV DNA. Data are collected from the Pharmacy records,
patients’ case notes and computerised laboratory investigations from iSoft
patient management database.
Results
A total of 145 patients who were treated with Lamivudine over
the last 10 years. By the end of 2010, there were 37 patients (25.52%) on
Lamivudine therapy. There was no difference in age or gender distribution
between those who were still on Lamivudine and those who were not. Of
the 145 patients, 18 (12.41%) achieved HBeAg seroconversion. Out of the
patients who achieved HBeAg seroconversion only 2 remained on
Lamivudine at the end of the study period. Out of the total of 145 patients,
12 achieved HBsAg loss and 4 patients lost HBsAg while on Lamivudine
therapy. Of the total 37 patients currently on Lamivudine, 18 (48.64%)
have negative HBV DNA. By the end of 2010, a total of 33 patients
remained negative for HBV DNA. However of the 33 patients who have
negative HBV DNA and still on the drug, only 1 patient achieved HBeAg
seroconversion and 2 patients lost HBeAg, but remained anti HBe negative;
no patients lost HBsAg. At the end of the study period 21 out of the
37 were on Lamivudine monotherapy.
Summary
Our data are consistent with previous published data. There
was no correlation of HBeAg seroconversion to Age, Sex, or pre-treatment ALT. 作者: StephenW 时间: 2011-8-4 13:54
这些论文作者和他们的工作地址。他们是来自澳大利亚。
N MUWANWELLA,1 N KONTORINIS,1 L TARQUINIO,1
J FLEXMAN,2 W CHENG1
1Department of Gastroenterology and Hepatology,
2Infectious Diseases, Royal Perth Hospital, WA作者: 买平安的 时间: 2011-8-6 20:47
StephenW 发表于 2011-8-6 20:31
这些论文作者和他们的工作地址。他们是来自澳大利亚。
N MUWANWELLA,1 N KONTORINIS,1 L TARQUINIO,1
J F ...